Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION: Sofosbuvir + Ribavirin in Treatment-Experienced HCV Genotype 2/3
NCT01604850Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of sofosbuvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Jun 2012; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01604850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604850.